What is the recommended follow-up guideline for subcentimeter thyroid nodules?

Follow-Up Guidelines for Subcentimeter Thyroid Nodules

For subcentimeter thyroid nodules without high-risk ultrasound features (EU-TIRADS 2-4), ultrasound monitoring is not mandatory, but if performed, should occur at 1-2 years after discovery, then every 2-4 years thereafter. 1

Risk-Stratified Surveillance Approach

The 2022 SFE-AFCE-SFMN consensus provides clear guidance based on nodule size and ultrasound characteristics:

Low-Risk Subcentimeter Nodules (EU-TIRADS 2-3-4)

• EU-TIRADS 4 nodules ≤5mm or EU-TIRADS 3 nodules <10mm: Ultrasound monitoring is not mandatory 1
• If surveillance is chosen: First follow-up at 1-2 years, then 2-4 years intervals 1
• Some evidence supports even longer intervals, with first check-up at 3 years 1

High-Suspicion Subcentimeter Nodules (EU-TIRADS 5)

Even when subcentimeter, EU-TIRADS 5 nodules require different management:

• If benign cytology (Bethesda II) obtained: Monitor every 1-2 years for 5 years, then space out if stable 1
• This closer surveillance addresses the 3-8.6% residual malignancy risk despite benign cytology 1

Key Clinical Context

The rationale for conservative surveillance: Most subcentimeter nodules remain stable over time. The data shows:

• Only 1-3% malignancy risk in nodules initially classified as benign 1
• New nodules appear in only 9-14% of patients over 5-10 years 1
• Nodule growth occurs in 11-29% over 5 years, but spontaneous decrease occurs in 13-18% 1

Important caveat: While guidelines recommend conservative surveillance for most subcentimeter nodules, research shows that when subcentimeter nodules with highly suspicious features undergo biopsy, malignancy rates can reach 38-56% 2, 3. This reflects selection bias—nodules chosen for biopsy already have concerning features. The key is proper initial ultrasound risk stratification.

When to Consider Fine-Needle Aspiration

For subcentimeter nodules, FNAB is generally not indicated based on size alone. However, consider FNAB if:

• EU-TIRADS 5 features present (regardless of size <10mm)
• Significant growth during surveillance (>2-3mm increase) 4
• Specific high-risk features: pure solid composition + hypoechogenicity, microcalcifications, taller-than-wide shape 5, 2

Special Populations Requiring Closer Attention

Risk factors for nodule growth that may warrant more vigilant surveillance:

• Male gender 1, 2
• Age <45 years 1, 2
• Multiple nodules present 1
• Volume >0.2 cm³ (approximately >7.5mm) 1

Discontinuation of Surveillance

Monitoring may be discontinued in elderly patients with long-standing, stable, non-suspicious nodular disease 1. This acknowledges that the clinical significance of detecting slow-growing malignancy diminishes with advancing age and limited life expectancy.

Common Pitfalls to Avoid

1. Over-surveillance: Repeating ultrasounds too frequently (e.g., every 6 months) is not evidence-based and increases healthcare costs without improving outcomes 1

2. Reflexive biopsy of all subcentimeter nodules: Size-based thresholds exist for good reason—most subcentimeter nodules, even when malignant, represent indolent papillary microcarcinomas with excellent prognosis 4

3. Ignoring ultrasound-cytology discordance: EU-TIRADS 5 nodules with benign cytology still carry 3-8.6% malignancy risk and require ongoing surveillance 1

4. Assuming growth equals malignancy: Benign nodules also grow over time; growth alone (without suspicious features) does not mandate immediate intervention 6